Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ALT 00

Drug Profile

ALT 00

Alternative Names: ALT-00

Latest Information Update: 20 Jan 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alterras Therapeutics
  • Class Anti-inflammatories; Antifibrotics; Small molecules; Vasodilators
  • Mechanism of Action Aminopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Acute lung injury

Most Recent Events

  • 16 Dec 2022 ALT 00 is available for licensing as of 06 Jan 2023. http://www.alterras-therapeutics.com/ (Alterras Therapeutics GmbH website, January 2023)
  • 15 Nov 2021 Preclinical trials in Acute lung injury (Combination therapy) in Austria (Parenteral)
  • 15 Nov 2021 Pharmacodynamics data from a preclinical studies in Acute lung injury released by Alterras Therapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top